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SURVEY OF LITERATURECurrent Literature ReviewEffects of testosterone administration for 3 years on sub-
clinical atherosclerosis progression in older men with low or
low-normal testosterone levels a randomized clinical trial
Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P,
Budoff M, Pencina KM, Vita J, Dzekov C, Mazer NA, Coviello
AD, Knapp PE, Hally K, Pinjic E, Yan M, Storer TW, Bhasin S.
JAMA 2015;314:570-581.Editorial Comment: Basaria et al assessed the long-term effect
of testosterone administration on common carotid artery intima-
media thickness and coronary artery calcium in older men with
low or low-normal testosterone levels.1 They failed to identify
signiﬁcant differences between testosterone treated patients and
controls, and one of their ﬁrst conclusions was that testosterone
administration for 3 years did not result in a signiﬁcant difference
in the terms of subclinical atherosclerosis progression. The results
are very interesting since many observational studies have shown
that low testosterone level is associated with an increased risk of
adverse cardiovascular outcomes and more pronounced signs of
atherosclerosis. The European cardiovascular prevention guide-
lines recommended (class IIa) both common carotid artery
intima-media thickness and coronary artery calcium for cardio-
vascular risk assessment in asymptomatic adults at moderate car-
diovascular risk.2 Subjects are considered to be at moderate risk
when their 10-year risk of a ﬁrst fatal atherosclerotic is comprised
between 1% and 5%. Many middle-aged subjects belong to this
category. Conversely, the role of both techniques on patients at
high cardiovascular risk such as old patients with a high preva-
lence of cardiovascular risk factors may be questionable since they
may already have an advanced atherosclerosis. Unfortunately, the
authors did not report the cumulative cardiovascular risk (for
example using the Framingham risk score or the European
heartscore). Looking at baseline characteristics, most patients were
hypertensive and taking statins suggesting a high baseline risk. In
addition, obesity, hyperlipidemia and diabetes mellitus were
common and the mean age was around 70s. Indeed, recent
studies have shown that the coronary artery calcium score
detected by multidetector-row computed tomography (MDCT)
include two different calcium types: a intimal deposition and a
medial accumulation of calcium across the coronary wall. While
the former has been associated with coronary plaque rupture, the
latter seems a passive and age-related accumulation of calcium.3
For this reason, the MDCTederived coronary artery calcium
score has a better prognostic role in young patients, when the
contribution of medial calcium accumulation is less interfering.Copyright ª 2016, International Society for Sexual Medicine. Published by
Elsevier Inc. All rights reserved.
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e2For all these considerations the present study cannot exclude
that in younger, low-risk subjects, hypogonadism may prevent or
delay atherosclerosis. Yet, the study is important, because,
although not primarily addressing CV safety (as none of other
previous studies, including the TOM trial), it seems to conﬁrm
the safety of testosterone use in the settings of randomized
controlled trials, as recently shown.4
As a secondary outcome, the authors also investigated sexual
function and healtherelated quality of life assessed using the
International Index of Erectile Function (IIEF-15) and the
Medical Outcomes Study 36-item short form health survey (SF-
36). The authors concluded that sexual desire, erectile function,
overall sexual function scores, partner intimacy, and health-
related quality of life did not signiﬁcantly differ between testos-
terone treated patients and controls. However, the results are
difﬁcult to interpret because of controversial enrollment criteria
and baseline characteristics of participants. In fact, the popula-
tion was not selected for signs or symptoms of hypogonadism,
nor sexual dysfunction. Therefore, as expected no changes was
expected in these domains.
These ﬁndings conﬁrm, once more, that replacement is not an
age-reversal drug, rather it is a replacement therapy that should
be given to men with biochemical and clinical evidence of
androgen deﬁciency to prevent sexual5 and systemic complica-
tions of hypogonadism, especially in young and middle-aged
men before these complications become irreversible.
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society clinical practice guideline
Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad
MH, Rosner W, Santoro N. J Clin Endocrinol Metab
2014;99:3489-510.Editorial Comment: The decline of circulating androgens in
pre- and post-menopausal women can be associated with a
decrease in sexual function, and an increase in personal distress
and anxiety. A replacement with testosterone in women has been
a matter of controversies for almost two decades. The skepticism
is mainly driven by the lack of valid reference ranges, very
low accuracy of assays measurement of testosterone in the low
(female) range and missing data on its safety.
Given this, the Endocrine Society commissioned a task force
to develop clinical practice guidelines for the use of androgen in
postmenopausal women.1
The major advancement of the Task Force has been to provide
a clear indication—and limitation—for testosterone therapy in
women, that is only in postmenopausal women suffering from
sexual dysfunction due to hypoactive sexual desire disorder
(HSDD). According to Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV), the deﬁnition of HSDD was deﬁ-
cient or absent sexual fantasies and desire for sexual activity
causing marked distress or interpersonal difﬁculty. Since it has
been established that low sexual desire and low arousal are
codependent, the two have been combined in DSM-V as
“desire earousal disorder.” Thus, the diagnosis of HSDD in-
cludes the presence of both reduced interest in sexual activity and
absent arousal from external sexual/erotic cues.2
At the moment, the evidence is not strong enough for
testosterone use for any other indication outside the treatment of
HSDD. Moreover, the actual randomized controlled trials, that
have studied the effect of testosterone on women, had a short
follow-up duration and do not allow to wave any safety concern.
In addition, the positive effects were lost when treatment was
continued for longer periods, suggesting a transient mechanism
of action. In light of these evidences, testosterone therapy should
be prescribed as trial, for 3- to 6-month period. Treated women
should be monitored carefully measuring testosterone levels at
baseline and after 3e6 weeks to assess patient misuse or abuse,
and signs of androgen excess such as acne and hirsutism. Therapy
cessation should be considered in all women who have not
responded to treatment by 6 months.
Most studies, investigating testosterone therapy for women,
used a transdermal testosterone patch changed twice a week. This
formulation is known for releasing approximately 300 mg ofSex Med 2016;4:e2ee6testosterone for day. Other transdermal testosterone formulations
and a skin spray have not obtained the ﬁnal approval for women,
yet. A transdermal 1% testosterone cream for women is available
in Australia. It has been shown to be effective and to have
consistent pharmacokinetic properties in small studies. Testos-
terone undecanoate, in a dose of 40 mg either daily or on
alternate days, is used in many countries. Unfortunately, this
compound has highly variable absorption and can results in levels
in the normal male range.3
The best available evidence demonstrates that the use of
testosterone either alone or with hormonal replacement therapy
has statistically signiﬁcant beneﬁcial effects on multiple domains
of sexual function in postmenopausal women. These outcomes
include the number of satisfying sexual episodes, frequency of
sexual activity, libido, orgasm, arousal, pleasure or enjoyment
of sex, sexual responsiveness, sexual self-image, and sexual or
relationship satisfaction.4
Despite the improvement in sexual function associated with
testosterone use in postmenopausal women, important consid-
erations for implementation of recommendation are needed.
Firstly, the length of treatment and monitoring procedures are
not well established. No safety and efﬁcacy data for testosterone
therapy are available for more the 24 month treatments.
Secondly, physiological testosterone preparations for clinical use
in women are not available in many countries, including the
United States.
Rigorously designed prospective observational studies could
have a major role in evaluating the safety proﬁle of testosterone
therapy together with speciﬁcally designed testosterone formu-
lations for women are welcome.
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salpingo-oophorectomy
Tucker PE, Bulsara MK, Salﬁnger SG, Tan JJ, Green H, Cohen
PA. Gynecol Oncol 2016 Jan;140:95-100.
e4 Survey of LiteratureEditorial Comment: It is well established that menopausal
status is associated with increased rates of sexual dysfunction.1
Further, numerous studies have shown that bilateral salpingo-
oophorectomy is associated with increased rates of sexual
dysfunction.2 Quality of life for cancer patients is an increasingly
important topic and sexual health has received a lot of attention
from multiple disciplines.3 Survivorship has is many ways
become its own area of concentration within oncology and for
associated specialists, especially the sexual medicine provider.
An important subset of women affected by cancer is women
who undergo bilateral salpingo-oophorectomy not for cancer
treatment but rather for cancer prevention. This surgery has
gained signiﬁcant attention in recent years based on what has
been dubbed the “Angelina Jolie” effect,4 which encompasses
women who undergo risk reducing mastectomy and salpingo-
oophorectomy based on a genetic predisposition to breast and
ovarian cancer.
The term “risk reducing” is usually associated with such
women who do not have cancer but are at high risk. There is
evidence that salpingo-oophorectomy does itself help treat breast
cancer in premenopausal women with hormone sensitive cancers.
For these women the term “risk reducing” is less applicable.
The focus on these deﬁnitions is critical in interpreting
the results of this study, which purports to assess the sexual
function in women undergoing risk reducing bilateral salpingo-
oophorectomy (RRSO).
This study is a cross sectional analysis of a cohort of women at
a tertiary care center in Western Australia. Women who un-
derwent RRSO were contacted and invited to complete a very
comprehensive set of validated questionnaires related to sexual
health and quality of life. Indeed, one of the greatest strengths of
this article is that is actually incorporates the FSFI and FSDS,
with which all specialists in sexual medicine are familiar. The
authors had a high response rate (58%) and a large number of
women (119) to include in this study. They found that there was
a high rate of risk for FSD and HSDD (74% and 73%) and
sexual distress rates were also high (49%). The majority of
women (80%) were sexually active but many (41%) reported
dissatisfaction with their sex lives. Most interesting was that the
main complaint for these women related to lubrication. Thus is
was not surprising that in the multivariable analysis self-reported
pain and less use of vaginal estrogen were most associated with
FSD, in addition to the relationship assessment score.
This data is very compelling but needs to be interpreted very
carefully. The women who were included had very high rates of
breast cancer (50%) as well as hysterectomy (89%), either at the
time of surgery or prior. Most important, however, is that the
majority of these women were already menopausal (57%) at the
time of surgery. Only 27% actually had a known genetic muta-
tion putting them at high risk for breast or ovarian cancer. Thus
calling their surgery “risk reducing” is a misnomer in some ways.
The current guidelines are for women to undergo RRSO age 35-40 years, long before menopause, and the role of hysterectomy in
these surgeries has not been well established.5 The fact that most
of these women were already menopausal highlights the other
limitation that there is no prospective component to this study;
that is we don’t know the sexual function of these women prior to
surgery. This means any associations between the surgery and the
sexual health effects need to be interpreted with great caution.
What should be taken away from this study is that a large
number of women experience sexual dysfunction, and there may
be an effect from gynecologic surgery in exacerbating their
symptoms. Thus all providers who care for these women can and
should assess sexual function and work to help improve this very
important health concern.
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Differences in pornography use among couples: associations
with satisfaction, stability, and relationship processes
Willoughby BJ, Carroll JS, Busby DM, Brown CC. Arch Sex
Behav 2016 45:145-58.
Editorial Comment: Pornography has been described as “a
driving force behind the technological development and
deployment of almost every type of media” (a quote attributed to
Jenkins in Feona Attwood’s book Porn.com.) There is little doubt
that use of pornography is very common, likely more so in the
modern era where it is readily accessible via the internet. In this
context, research on how porn affects sexuality (in the context of
both individuals and dyads) is of great relevance.
This unique study studied use of pornography in the context
of a large sample of heterosexual couples. A great deal of existing
literature has suggested that communication and sexual difﬁ-
culties within the dyad are associated with pornography use but,
to date, few studies have examined pornography use/opinions in
both partners of a couple.
The authors of this scale developed a metric to assess use of
and acceptance of pornography within partners of a dyad;Sex Med 2016;4:e2ee6
Survey of Literature e5approximately one-third of all couples endorsed a similar fre-
quency of pornography use, with about 6% reporting no use for
either partner. As might be expected, there was a positive asso-
ciation between communication, satisfaction, and stability in the
context of concordant use and acceptance of pornography for
both partners.
Pornography is oftentimes cited as an impediment to relation-
ships and in some cases this is no doubt true.However, data such as
these suggest that it is disagreement within the dyad about
pornography that drives at least some of the negative consequences
often attributed to pornography itself. These data should be
considered when addressing sexuality in the context of a couple and
differences in use (and acceptance) of erotic materials explored as a
potential contributor to erosion of trust and attachment.
Alan W. Shindel, MD, MASIdentiﬁcation with stimuli moderates women’s affective and
testosterone responses to self-chosen erotica
Goldey KL, van Anders SM. Arch Sex Behav 2015. In press.Editorial Comment: Erotic material (most commonly audio-
visual sexual stimulation or AVSS) is widely utilized in sexuality
research, particular in studies of arousal patterns as a factor of
mental and physical state. Much of the AVSS used in sexuality
research is selected for its depiction of sexual activities generally
regarding as appealing by the majority of likely viewers (eg,
consensual foreplay, oral sex, and coitus in the context of het-
erosexual viewers) with the intent of being as universal as
possible. While such selections may be generally appealing to
most viewers, individual sexual preference is so varied that no
researcher-selected AVSS can possible evoke a standardized level
of expected response in every subject exposed.
The authors of this study attempt to study variation in af-
fective response to researcher versus subject selected erotica.
Women were assigned to one of three types of erotic stimuli: (1)
using erotic material entirely of their own choosing; (2) choosing
from a selection of erotic materials provided by the researchers;
and (3) having erotica assigned by the researchers.
As expected, women given control and choice about the erotic
material to which they were exposed endorsed greater degrees of
arousal. While this ﬁnding is not surprising, what was of particular
interest was that women using self-selected erotica weremore likely
to report embarrassment and feelings of guilt. This effect was most
pronounced when the participant women reported low or mod-
erate levels of identiﬁcation with the performers in the erotic
materials.
In this research setting all subjects were aware that they were to be
exposed to sexually explicit media and reported comfort with that
type of material. Is actively “choosing” the type of erotica (rather
than having it simply provided) the reason for negative feelings suchSex Med 2016;4:e2ee6as guilt? The association between lack of identiﬁcation and guilt is
particularly intriguing. It may be hypothesized that this low iden-
tiﬁcation leaves thewoman viewing feelingmore like a voyeur than a
participant in an erotic encounter; alternatively, itmay sometimes be
the case that the woman viewing ﬁnds the activity sexually arousing
but mentally/emotionally unappealing and hence rejects it by
refusing to identify with it.
These ﬁndings are relevant and interesting to investigators
who utilize AVSS or other erotic stimuli in research settings and
to clinicians who are inﬂuenced by their ﬁndings. In the future it
may be the case that some form of “pre-screening” for sexual
preferences and selection of concordant AVSS may facilitate
maximal arousal without invoking feelings of guilt in this type of
research.
Alan W. Shindel, MD, MASShame, catastrophizing, and negative partner responses are
associated with lower sexual and relationship satisfaction
and more negative affect in men with Peyronie’s disease
Davis S, Ferrar S, Sadikaj G, Binik Y, Carrier S. J Sex Marital
Ther 2016. In press.Editorial Comment: Nelson et al have reported on the
long term psychological and interpersonal consequences of Peyr-
onie’s disease (PD); importantly, these researchers have deter-
mined in cross-sectional studies that duration of PD does not
materially impact upon degree of psychological distress.1 While
these studies are not longitudinal and hence causation cannot be
gleaned, it is reasonable to postulate that the psychological burden
of PD does not diminish over time as some other may occur with
other ailments to which men become habituated.
Another interesting ﬁnding in the existing PD literature is
that degree of deformity is only weakly correlate to subjective
distress.2 It can be deduced that the emotional and psycholog-
ical burden of PD is mediated in large part by how the man
(and his partner) react to the diagnosis This paper explores inter
and intrapersonal factors that mediate the relative burden of
PD in a given man. The authors used a combination of vali-
dated and non-validated metrics (eg, catastrophizing was
measured using the Pain Catastrophizing Scale with the phrase
“Peyronie’s Disease” put in place of “pain” for all questions and
partner negative and solicitous responses were measured using
an adapted version of the West-Haven-Yale multidimensional
pain inventory).
The authors conclude that a tendency to catastrophize (ie,
treating negative events as inordinately traumatic), negative
partners responses to PD, and shame were associated with worse
emotional, sexual, and relationship functioning related to PD.
There was a range of response, with some men reasonably well
adapted to their PD condition.
e6 Survey of LiteratureGiven that existing treatments for PD may not reliably and
consistently lead to complete reversal, attention to these psycho-
logical components of the diagnosis are essential for practitioners.
Involvement of a mental health specialist and/or careful attention to
catastrophizing, body image, and relationship issues by the primary
treating physician are essential to optimizing outcomes in PD
patients.
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